HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

miR-425-5p suppresses tumorigenesis and DDP resistance in human-prostate cancer by targeting GSK3β and inactivating the Wnt/β-catenin signaling pathway.

Abstract
Prostate cancer (PCa) represents the most frequently diagnosed cancer in men. Cisplatin, also known as cis-diamminedichloroplatinum (DDP), is a standard chemotherapeutic agent used to treat PCa, and DDP resistance remains one important obstacle in DDP-based chemotherapy. In our research, we found miR-425-5p was down-regulated in PCa and even lower in DDP-resistant PCa determined by quantitative polymerase chain reaction; in contrast, GSK3β mRNA expression was upregulated in PCa and even higher in DDP-resistant PCa. Moreover, there was a modest but significant inverse correlation between the expression of GSK3β mRNA and miR-425-5p. Functional experiments showed that miR-425-5p mimic inhibited DDP resistance as evidenced by a promoted apoptosis rate (flow cytometry) and suppressed cell viability (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay) and expressions of MDR1 andMRP1 (western blotting) in DU145/DDP and PC3/DDP cells. Luciferase reporter assay and RNA immunoprecipitation identifiedGSK3β was a potential target of miR-425-5p. The effect ofmiR-425-5pmimic on DDP resistance was partially reversed by pcDNA-GSK3β. Mechanically, miR-425-5p mimic reduced expression of β-catenin, cyclin D1 and C-myc, which was further blocked when GSK3β overexpressed. In vivo experiments, recovery of GSK3β prevented xenograft tumor growth and DDP resistance in the presence of miR-425-5p mimic. To sum up, miR-425-5p upregulation might sensitize human PCa to DDP by targeting GSK3β and inactivating the Wnt/β-catenin signaling pathway.
AuthorsSheng Liu, Qin Wang, Yin Liu, Zong-Yu Xia
JournalJournal of biosciences (J Biosci) Vol. 44 Issue 4 (Sep 2019) ISSN: 0973-7138 [Electronic] India
PMID31502580 (Publication Type: Journal Article)
Chemical References
  • CTNNB1 protein, human
  • MIRN425 microRNA, human
  • MicroRNAs
  • beta Catenin
  • Glycogen Synthase Kinase 3 beta
  • Cisplatin
Topics
  • Animals
  • Apoptosis (drug effects)
  • Carcinogenesis (genetics)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cisplatin (pharmacology)
  • Drug Resistance, Neoplasm
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Glycogen Synthase Kinase 3 beta (genetics)
  • Humans
  • Male
  • Mice
  • MicroRNAs (genetics)
  • Prostatic Neoplasms (drug therapy, genetics, pathology)
  • Wnt Signaling Pathway (drug effects)
  • Xenograft Model Antitumor Assays
  • beta Catenin (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: